Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
Tag: AMNOG process
The four most important things to know about pricing in Germany
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
Prof. Dr. Karl Lauterbach is the new German health minister
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot
New government coalition plans AMNOG, pricing and other reforms
The new government in Germany is formed as a coalition of the three parties, SDP, FDP and the Green Party. At the
The biggest SHI fund, the AOK, proposes an end to free pricing in Germany
Currently, free pricing of products with a new chemical entity (NCE) applies in the first year. This means, at the time of